ALK achieved satisfactory growth in sales and earnings exceeding the
expectations in a number of areas.

In Q4, revenue increased organically by 13% and for 2009 as a whole revenue
totalled DKK 1,935 million. The organic growth in vaccine sales was 10%.

In Q4, operating profit (EBIT) was DKK 58 million and for 2009, EBIT totalled
DKK 175 million.

For 2010, ALK forecasts sustained growth in both sales and earnings. However,
earnings will be affected by rising costs as a result of increased regulatory
requirements in Europe and the intensified collaboration with Merck to develop
and launch tablets in North America.

See page 2 in the attached annual report for 2009 for further highlights.

The company invites analysts and investors to a meeting with Management
tomorrow, at 09.00 a.m. (CET) at Heerings Gaard, Overgaden neden Vandet 11,
0900 Copenhagen C, at Nordea.

The meeting will be held in English and webcast live on www.alk-abello.com. It
will be possible to call in with questions.

Participants in the conference call are kindly requested to call in before 8.55
a.m. (CET). Danish participants should call in on tel +45 7026 5040 or +45 3271
4767 and international participants should call in on tel +44 208 817 9301.

ALK-Abelló A/S

Jens Bager
President and CEO

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. + 45 4574 7901, mobile + 45 2064 1143

fm-05-10-uk-annualreport2009.pdf